{
    "clinical_study": {
        "@rank": "132683", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "No Intervention", 
                "description": "Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX)."
            }, 
            {
                "arm_group_label": "TMP/SMX", 
                "arm_group_type": "Experimental", 
                "description": "Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis."
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluation the efficacy and safety profile of trimethoprim/sulfamethoxazole as Pneumocystis\n      carinii pneumonia (PCP) prophylaxis in Patients With Connective Tissue Diseases (CTD)\n      treated with high-dose glucocorticoids and immunosuppressive agents.\n\n      Open-labeled, randomized, prospective single-center clinical trial. Observation period of 12\n      weeks."
        }, 
        "brief_title": "Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pneumonia, Pneumocystis", 
            "Prevention & Control"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Connective Tissue Diseases", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-65 years with informed consent\n\n          -  SLE, Sj\u00f6gren syndrome, Polymyositis or  Dermatomyositis, defined by consensus\n             classification criteria\n\n          -  concomitant high dose glucocorticoid, defined as >1mg/kg/d prednisone or equivalent\n\n          -  concomitant cyclophosphamide, cyclosporine or mycophenolate mofetil\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating\n\n          -  WBC\uff1c 4\u00d710^9/L\uff0cPLT\uff1c100\u00d710^9/L\n\n          -  Serum ALT or AST > 2 times upper limit of normal\n\n          -  Serum creatinine > 1.5 mg/dL\n\n          -  Severe hepatic, hematological, gastrointestinal, pulmonary, cardiovascular,\n             neurological, endocrine or cerebral disease\n\n          -  Active infection, including HIV, HCV, HBV, tuberculosis or PCP\n\n          -  concomitant  antibiotics other than trimethoprim/sulfamethoxazole\n\n          -  Patient with malignancy\n\n          -  Drug allergy, especially trimethoprim/sulfamethoxazole"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747278", 
            "org_study_id": "PUMCH-CTD-PCP"
        }, 
        "intervention": {
            "arm_group_label": "TMP/SMX", 
            "description": "Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.", 
            "intervention_name": "Trimethoprim/Sulfamethoxazole", 
            "intervention_type": "Drug", 
            "other_name": "Septra"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sulfamethoxazole", 
                "Trimethoprim"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pneumocystis carinii pneumonia", 
            "prophylaxis", 
            "trimethoprim/sulfamethoxazole"
        ], 
        "lastchanged_date": "December 9, 2012", 
        "location": {
            "contact": {
                "email": "ZhangFCcra@yahoo.com.cn", 
                "last_name": "Fengchun Zhang, MD", 
                "phone": "+86-10-69158794"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100032"
                }, 
                "name": "Deptment of Rheumatology, Peking Union Medical College Hospital"
            }, 
            "investigator": {
                "last_name": "Fengchun Zhang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases", 
        "overall_contact": {
            "email": "chenhua@pumch.cn", 
            "last_name": "Hua Chen, MD", 
            "phone": "+86-10-69158797"
        }, 
        "overall_official": {
            "affiliation": "Peking Union Medical College Hospital", 
            "last_name": "Fengchun Zhang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: National Natural Science Foundation", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Documented Pneumocystis carinii pneumonia infection: defined as documentation of Pneumocystis from a properly obtained specimen (induced sputum, bronchoalveolar lavage, or biopsy) in a patient with clinical manifestations compatible with PCP.", 
            "measure": "Documented PCP infection", 
            "safety_issue": "No", 
            "time_frame": "12 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747278"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking Union Medical College Hospital", 
            "investigator_full_name": "Fengchun Zhang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "PCP-related mortality at the end of week 12.", 
                "measure": "PCP-related mortality", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "All cause mortality at the end of week 12.", 
                "measure": "All cause mortality", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Infections other than PCP throughout the study period.", 
                "measure": "Other infections", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "PCP-related hospitalization throughout the study period.", 
                "measure": "PCP-related hospitalization", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}